...
首页> 外文期刊>Pharmaceutical research >Active apical secretory efflux of the HIV protease inhibitors saquinavir and ritonavir in Caco-2 cell monolayers (published erratum appears in Pharm Res 1998 Jun;15(6):958)
【24h】

Active apical secretory efflux of the HIV protease inhibitors saquinavir and ritonavir in Caco-2 cell monolayers (published erratum appears in Pharm Res 1998 Jun;15(6):958)

机译:HIV蛋白酶抑制剂沙奎那韦和利托那韦在Caco-2细胞单层中的主动根尖分泌外流(发表的勘误表见Pharm Res 1998 Jun; 15(6):958)

获取原文
获取原文并翻译 | 示例
           

摘要

PURPOSE: To investigate in vitro the mechanisms involved in the gastro-intestinal absorption of the HIV protease inhibitor, saquinavir mesylate (Invirase), whose oral bioavailability is low, variable, and significantly increased by co-administration with ritonavir, also an HIV protease inhibitor but with higher oral bioavailability. METHODS: Confluent epithelial layers of human Caco-2 cells mimicking the intestinal barrier. RESULTS: Both saquinavir and ritonavir showed polarized transport through Caco-2 cell monolayers in the basolateral to apical direction (secretory pathway), exceeding apical to basolateral transport (absorptive pathway) by factors of 50-70 and 15-25, respectively. Active efflux was temperature dependent, saturable and inhibited by verapamil and cyclosporin A. Saquinavir and ritonavir decreased each other's secretory permeability and hence elevated their net transport by the absorptive pathway. CONCLUSIONS: Saquinavir and ritonavir are both substrates for an efflux mechanism in the gut, most likely P-glycoprotein, which acts as a counter-transporter for both drugs. Together with sensitivity to gutwall metabolism by cytochrome P-450 3A, this may partially account for the low and variable oral bioavailability of saquinavir in clinical studies and for its increased bioavailability after co-administration with ritonavir.
机译:目的:体外研究HIV蛋白酶抑制剂甲磺酸沙奎那韦(Invirase)在胃肠道中的吸收机制,其口服生物利用度低,易变,并与利妥那韦(一种HIV蛋白酶抑制剂)合用会显着增加但口服生物利用度更高。方法:人Caco-2细胞的融合上皮层模拟肠屏障。结果:沙奎那韦和利托那韦均显示出从Caco-2细胞单层在基底外侧向顶端方向(分泌途径)的极化转运,分别超过了从顶端到基底外侧转运(吸收途径)的50-70和15-25倍。主动外排是温度依赖性的,可被维拉帕米和环孢菌素A饱和并抑制。沙奎那韦和利托那韦降低了彼此的分泌通透性,因此通过吸收途径提高了其净转运。结论:沙奎那韦和利托那韦都是肠道外排机制的底物,最可能是P糖蛋白,可作为两种药物的逆转运蛋白。再加上细胞色素P-450 3A对肠壁代谢的敏感性,这可能部分解释了沙奎那韦在临床研究中口服生物利用度低而可变,以及与利托那韦共同给药后其生物利用度增加。

著录项

相似文献

  • 外文文献
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号